Can a DNA-Based therapy revive Chemotherapy's power against resistant ovarian cancer?
Disease control
Completed
This phase 2 trial is investigating whether adding an experimental DNA-based therapy called ELENAGEN to the chemotherapy drug gemcitabine can help people with platinum-resistant ovarian cancer. The study will compare the combination against gemcitabine alone, measuring how long p…
Phase 2 • Sponsor: CureLab Oncology • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC